Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens
We studied the serum bactericidal activity (SBA) of moxifloxacin and levofloxacin against common pathogens associated with complicated intra-abdominal infections. Ten healthy volunteers received a single dose of moxifloxacin (400 mg) and levofloxacin (750 mg) and serum samples were collected at 2, 4...
Gespeichert in:
| Veröffentlicht in: | Anaerobe 2008-02, Vol.14 (1), p.8-12 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 12 |
|---|---|
| container_issue | 1 |
| container_start_page | 8 |
| container_title | Anaerobe |
| container_volume | 14 |
| creator | Stein, Gary E. Schooley, Sharon Tyrrell, Kerin L. Citron, Diane M. Nicolau, David P. Goldstein, Ellie J.C. |
| description | We studied the serum bactericidal activity (SBA) of moxifloxacin and levofloxacin against common pathogens associated with complicated intra-abdominal infections. Ten healthy volunteers received a single dose of moxifloxacin (400
mg) and levofloxacin (750
mg) and serum samples were collected at 2, 4, 8, 12, and 24
h after the dose of each drug. Bactericidal titers in serum over time were determined for aerobic gram-negative bacilli (
Escherichia coli,
Klebseilla pneumoniae, and
Enterobacter cloacae) and anaerobic bacteria (
Bacteroides fragilis,
Bacteroides thetaiotaomicron,
Prevotella bivia, and
Finegoldia magna). Both fluoroquinolones provided rapid (2
h) attainment and prolonged (24
h) SBA (titers ⩾1:8) against each of the aerobic bacilli studied. SBA was observed for at least 12
h against
B. fragilis strains with MICs⩽2
μg/ml to moxifloxacin and ⩽4
μg/ml to levofloxacin. Prolonged (12
h) SBA (titers ⩾1:2) was also observed against isolates of
B. thetaiotaomicron,
P. bivia, and
F. magna with moxifloxacin MICs⩽2
μg/ml. |
| doi_str_mv | 10.1016/j.anaerobe.2007.09.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70302528</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1075996407000789</els_id><sourcerecordid>70302528</sourcerecordid><originalsourceid>FETCH-LOGICAL-c397t-2b699c0cb4bdf8f6768788fe370efcbab97bce06e987efaaff0aea462dc2055a3</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi1ERUvbv1DlxC1h8mE7voEqCkiVOEDP1tgZF68Se7Gzq_Lv8XYX9diTx9Yz74z8MHbTQtNCKz5uGgxIKRpqOgDZgGoA-Bt20YLi9djJ4e2hlrxWSgzn7H3OG4C2HTh_x85bqcZeSrhg-5-Udktl0K6UvPUTzlWp_d6vnnIVXbXEJ-_m-ITWhwrDVM20jy8Pj-hDXqvnXbx9Bk6blZsPa8IazRQXH0ryFtff8ZFCvmJnDudM16fzkj3cffl1-62-__H1--3n-9r2Sq51Z4RSFqwZzORGJ6QY5Tg66iWQswaNksYSCFKjJIfoHCDhILrJdsA59pfswzF3m-KfHeVVLz5bmmcMFHdZS-ih4934Klji-l50vIDiCNoUc07k9Db5BdNf3YI-qNEb_V-NPqjRoHRRUxpvThN2ZqHppe3kogCfjgCVD9l7SjpbT8HS5BPZVU_RvzbjH4Cmp0E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20533625</pqid></control><display><type>article</type><title>Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Stein, Gary E. ; Schooley, Sharon ; Tyrrell, Kerin L. ; Citron, Diane M. ; Nicolau, David P. ; Goldstein, Ellie J.C.</creator><creatorcontrib>Stein, Gary E. ; Schooley, Sharon ; Tyrrell, Kerin L. ; Citron, Diane M. ; Nicolau, David P. ; Goldstein, Ellie J.C.</creatorcontrib><description>We studied the serum bactericidal activity (SBA) of moxifloxacin and levofloxacin against common pathogens associated with complicated intra-abdominal infections. Ten healthy volunteers received a single dose of moxifloxacin (400
mg) and levofloxacin (750
mg) and serum samples were collected at 2, 4, 8, 12, and 24
h after the dose of each drug. Bactericidal titers in serum over time were determined for aerobic gram-negative bacilli (
Escherichia coli,
Klebseilla pneumoniae, and
Enterobacter cloacae) and anaerobic bacteria (
Bacteroides fragilis,
Bacteroides thetaiotaomicron,
Prevotella bivia, and
Finegoldia magna). Both fluoroquinolones provided rapid (2
h) attainment and prolonged (24
h) SBA (titers ⩾1:8) against each of the aerobic bacilli studied. SBA was observed for at least 12
h against
B. fragilis strains with MICs⩽2
μg/ml to moxifloxacin and ⩽4
μg/ml to levofloxacin. Prolonged (12
h) SBA (titers ⩾1:2) was also observed against isolates of
B. thetaiotaomicron,
P. bivia, and
F. magna with moxifloxacin MICs⩽2
μg/ml.</description><identifier>ISSN: 1075-9964</identifier><identifier>EISSN: 1095-8274</identifier><identifier>DOI: 10.1016/j.anaerobe.2007.09.005</identifier><identifier>PMID: 17983770</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Abdominal Cavity - microbiology ; Adult ; Anaerobes ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - blood ; Anti-Bacterial Agents - pharmacology ; Aza Compounds - administration & dosage ; Aza Compounds - blood ; Aza Compounds - pharmacology ; Bacteria, Aerobic - drug effects ; Bacteria, Anaerobic - drug effects ; Bacteroides ; Bacteroides fragilis ; Bacteroides thetaiotaomicron ; Enterobacter cloacae ; Escherichia coli ; Female ; Fluoroquinolones ; Humans ; Intra-abdominal ; Levofloxacin ; Male ; Middle Aged ; Moxifloxacin ; Ofloxacin - administration & dosage ; Ofloxacin - blood ; Ofloxacin - pharmacology ; Prevotella bivia ; Quinolines - administration & dosage ; Quinolines - blood ; Quinolines - pharmacology ; Serum Bactericidal Test</subject><ispartof>Anaerobe, 2008-02, Vol.14 (1), p.8-12</ispartof><rights>2007 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c397t-2b699c0cb4bdf8f6768788fe370efcbab97bce06e987efaaff0aea462dc2055a3</citedby><cites>FETCH-LOGICAL-c397t-2b699c0cb4bdf8f6768788fe370efcbab97bce06e987efaaff0aea462dc2055a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.anaerobe.2007.09.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17983770$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stein, Gary E.</creatorcontrib><creatorcontrib>Schooley, Sharon</creatorcontrib><creatorcontrib>Tyrrell, Kerin L.</creatorcontrib><creatorcontrib>Citron, Diane M.</creatorcontrib><creatorcontrib>Nicolau, David P.</creatorcontrib><creatorcontrib>Goldstein, Ellie J.C.</creatorcontrib><title>Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens</title><title>Anaerobe</title><addtitle>Anaerobe</addtitle><description>We studied the serum bactericidal activity (SBA) of moxifloxacin and levofloxacin against common pathogens associated with complicated intra-abdominal infections. Ten healthy volunteers received a single dose of moxifloxacin (400
mg) and levofloxacin (750
mg) and serum samples were collected at 2, 4, 8, 12, and 24
h after the dose of each drug. Bactericidal titers in serum over time were determined for aerobic gram-negative bacilli (
Escherichia coli,
Klebseilla pneumoniae, and
Enterobacter cloacae) and anaerobic bacteria (
Bacteroides fragilis,
Bacteroides thetaiotaomicron,
Prevotella bivia, and
Finegoldia magna). Both fluoroquinolones provided rapid (2
h) attainment and prolonged (24
h) SBA (titers ⩾1:8) against each of the aerobic bacilli studied. SBA was observed for at least 12
h against
B. fragilis strains with MICs⩽2
μg/ml to moxifloxacin and ⩽4
μg/ml to levofloxacin. Prolonged (12
h) SBA (titers ⩾1:2) was also observed against isolates of
B. thetaiotaomicron,
P. bivia, and
F. magna with moxifloxacin MICs⩽2
μg/ml.</description><subject>Abdominal Cavity - microbiology</subject><subject>Adult</subject><subject>Anaerobes</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - blood</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Aza Compounds - administration & dosage</subject><subject>Aza Compounds - blood</subject><subject>Aza Compounds - pharmacology</subject><subject>Bacteria, Aerobic - drug effects</subject><subject>Bacteria, Anaerobic - drug effects</subject><subject>Bacteroides</subject><subject>Bacteroides fragilis</subject><subject>Bacteroides thetaiotaomicron</subject><subject>Enterobacter cloacae</subject><subject>Escherichia coli</subject><subject>Female</subject><subject>Fluoroquinolones</subject><subject>Humans</subject><subject>Intra-abdominal</subject><subject>Levofloxacin</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Moxifloxacin</subject><subject>Ofloxacin - administration & dosage</subject><subject>Ofloxacin - blood</subject><subject>Ofloxacin - pharmacology</subject><subject>Prevotella bivia</subject><subject>Quinolines - administration & dosage</subject><subject>Quinolines - blood</subject><subject>Quinolines - pharmacology</subject><subject>Serum Bactericidal Test</subject><issn>1075-9964</issn><issn>1095-8274</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhi1ERUvbv1DlxC1h8mE7voEqCkiVOEDP1tgZF68Se7Gzq_Lv8XYX9diTx9Yz74z8MHbTQtNCKz5uGgxIKRpqOgDZgGoA-Bt20YLi9djJ4e2hlrxWSgzn7H3OG4C2HTh_x85bqcZeSrhg-5-Udktl0K6UvPUTzlWp_d6vnnIVXbXEJ-_m-ITWhwrDVM20jy8Pj-hDXqvnXbx9Bk6blZsPa8IazRQXH0ryFtff8ZFCvmJnDudM16fzkj3cffl1-62-__H1--3n-9r2Sq51Z4RSFqwZzORGJ6QY5Tg66iWQswaNksYSCFKjJIfoHCDhILrJdsA59pfswzF3m-KfHeVVLz5bmmcMFHdZS-ih4934Klji-l50vIDiCNoUc07k9Db5BdNf3YI-qNEb_V-NPqjRoHRRUxpvThN2ZqHppe3kogCfjgCVD9l7SjpbT8HS5BPZVU_RvzbjH4Cmp0E</recordid><startdate>20080201</startdate><enddate>20080201</enddate><creator>Stein, Gary E.</creator><creator>Schooley, Sharon</creator><creator>Tyrrell, Kerin L.</creator><creator>Citron, Diane M.</creator><creator>Nicolau, David P.</creator><creator>Goldstein, Ellie J.C.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20080201</creationdate><title>Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens</title><author>Stein, Gary E. ; Schooley, Sharon ; Tyrrell, Kerin L. ; Citron, Diane M. ; Nicolau, David P. ; Goldstein, Ellie J.C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c397t-2b699c0cb4bdf8f6768788fe370efcbab97bce06e987efaaff0aea462dc2055a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Abdominal Cavity - microbiology</topic><topic>Adult</topic><topic>Anaerobes</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - blood</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Aza Compounds - administration & dosage</topic><topic>Aza Compounds - blood</topic><topic>Aza Compounds - pharmacology</topic><topic>Bacteria, Aerobic - drug effects</topic><topic>Bacteria, Anaerobic - drug effects</topic><topic>Bacteroides</topic><topic>Bacteroides fragilis</topic><topic>Bacteroides thetaiotaomicron</topic><topic>Enterobacter cloacae</topic><topic>Escherichia coli</topic><topic>Female</topic><topic>Fluoroquinolones</topic><topic>Humans</topic><topic>Intra-abdominal</topic><topic>Levofloxacin</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Moxifloxacin</topic><topic>Ofloxacin - administration & dosage</topic><topic>Ofloxacin - blood</topic><topic>Ofloxacin - pharmacology</topic><topic>Prevotella bivia</topic><topic>Quinolines - administration & dosage</topic><topic>Quinolines - blood</topic><topic>Quinolines - pharmacology</topic><topic>Serum Bactericidal Test</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stein, Gary E.</creatorcontrib><creatorcontrib>Schooley, Sharon</creatorcontrib><creatorcontrib>Tyrrell, Kerin L.</creatorcontrib><creatorcontrib>Citron, Diane M.</creatorcontrib><creatorcontrib>Nicolau, David P.</creatorcontrib><creatorcontrib>Goldstein, Ellie J.C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Anaerobe</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stein, Gary E.</au><au>Schooley, Sharon</au><au>Tyrrell, Kerin L.</au><au>Citron, Diane M.</au><au>Nicolau, David P.</au><au>Goldstein, Ellie J.C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens</atitle><jtitle>Anaerobe</jtitle><addtitle>Anaerobe</addtitle><date>2008-02-01</date><risdate>2008</risdate><volume>14</volume><issue>1</issue><spage>8</spage><epage>12</epage><pages>8-12</pages><issn>1075-9964</issn><eissn>1095-8274</eissn><abstract>We studied the serum bactericidal activity (SBA) of moxifloxacin and levofloxacin against common pathogens associated with complicated intra-abdominal infections. Ten healthy volunteers received a single dose of moxifloxacin (400
mg) and levofloxacin (750
mg) and serum samples were collected at 2, 4, 8, 12, and 24
h after the dose of each drug. Bactericidal titers in serum over time were determined for aerobic gram-negative bacilli (
Escherichia coli,
Klebseilla pneumoniae, and
Enterobacter cloacae) and anaerobic bacteria (
Bacteroides fragilis,
Bacteroides thetaiotaomicron,
Prevotella bivia, and
Finegoldia magna). Both fluoroquinolones provided rapid (2
h) attainment and prolonged (24
h) SBA (titers ⩾1:8) against each of the aerobic bacilli studied. SBA was observed for at least 12
h against
B. fragilis strains with MICs⩽2
μg/ml to moxifloxacin and ⩽4
μg/ml to levofloxacin. Prolonged (12
h) SBA (titers ⩾1:2) was also observed against isolates of
B. thetaiotaomicron,
P. bivia, and
F. magna with moxifloxacin MICs⩽2
μg/ml.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>17983770</pmid><doi>10.1016/j.anaerobe.2007.09.005</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1075-9964 |
| ispartof | Anaerobe, 2008-02, Vol.14 (1), p.8-12 |
| issn | 1075-9964 1095-8274 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70302528 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Abdominal Cavity - microbiology Adult Anaerobes Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - blood Anti-Bacterial Agents - pharmacology Aza Compounds - administration & dosage Aza Compounds - blood Aza Compounds - pharmacology Bacteria, Aerobic - drug effects Bacteria, Anaerobic - drug effects Bacteroides Bacteroides fragilis Bacteroides thetaiotaomicron Enterobacter cloacae Escherichia coli Female Fluoroquinolones Humans Intra-abdominal Levofloxacin Male Middle Aged Moxifloxacin Ofloxacin - administration & dosage Ofloxacin - blood Ofloxacin - pharmacology Prevotella bivia Quinolines - administration & dosage Quinolines - blood Quinolines - pharmacology Serum Bactericidal Test |
| title | Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T19%3A56%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20bactericidal%20activities%20of%20moxifloxacin%20and%20levofloxacin%20against%20aerobic%20and%20anaerobic%20intra-abdominal%20pathogens&rft.jtitle=Anaerobe&rft.au=Stein,%20Gary%20E.&rft.date=2008-02-01&rft.volume=14&rft.issue=1&rft.spage=8&rft.epage=12&rft.pages=8-12&rft.issn=1075-9964&rft.eissn=1095-8274&rft_id=info:doi/10.1016/j.anaerobe.2007.09.005&rft_dat=%3Cproquest_cross%3E70302528%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20533625&rft_id=info:pmid/17983770&rft_els_id=S1075996407000789&rfr_iscdi=true |